Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid

While strong cash flow is a key indicator of stability, it doesn't always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that reinvests wisely to drive long-term success and two best left off your watchlist.

Two Stocks to Sell:

Lindsay (LNN)

Trailing 12-Month Free Cash Flow Margin: 11.3%

A pioneer in the field of center pivot and lateral move irrigation, Lindsay (NYSE:LNN) provides a variety of proprietary water management and road infrastructure products and services.

Why Are We Wary of LNN?

Flat sales over the last two years suggest it must find different ways to grow during this cycle Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term Waning returns on capital imply its previous profit engines are losing steam

Lindsay's stock price of $114.74 implies a valuation ratio of 18.4x forward P/E. Read our free research report to see why you should think twice about including LNN in your portfolio, it's free.

ICU Medical (ICUI)

Trailing 12-Month Free Cash Flow Margin: 4.2%

Founded in 1984 and named for its initial focus on intensive care units, ICU Medical (NASDAQ:ICUI) develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.

Why Are We Cautious About ICUI?

Sales tumbled by 1.6% annually over the last two years, showing market trends are working against it during this cycle Performance over the past five years shows its incremental sales were less profitable, as its 2.9% annual earnings per share growth trailed its revenue gains ROIC of 0.9% reflects management's challenges in identifying attractive investment opportunities

At $142.82 per share, ICU Medical trades at 16.8x forward P/E. Check out our free in-depth research report to learn more about why ICUI doesn't pass our bar.

One Stock to Buy:

DoorDash (DASH)

Trailing 12-Month Free Cash Flow Margin: 11.9%

Founded by Stanford students with the intent to build "the local, on-demand FedEx", DoorDash (NASDAQ:DASH) operates an on-demand food delivery platform.

Why Is DASH a Good Business?

Orders have grown by 22.9% annually, allowing for more profitable cross-selling opportunities if it can build complementary products and features Expected revenue growth of 25.6% for the next year suggests its market share will rise Additional sales over the last three years increased its profitability as the 179% annual growth in its earnings per share outpaced its revenue

Story Continues

DoorDash is trading at $154.56 per share, or 16.7x forward EV/EBITDA. Is now a good time to buy? Find out in our full research report, it's free.

Stocks We Like Even More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Intravenöse (IV)-Flüssigkeitsmarkt wird als ein wachsender Markt angesehen, der von verschiedenen Faktoren beeinflusst wird. Die Marktdynamik umfasst Treiber, Einschränkungen und Chancen, die für die Unternehmen im Markt relevant sind. Der Bericht bietet eine detaillierte Analyse des globalen IV-Flüssigkeitsmarktes, einschließlich der Segmentierung nach Material, Anwendung und Industriezweig. Die Studie enthält auch Informationen über die wichtigsten Akteure auf dem Markt, ihre Strategien und Produkte. Der Bericht ist ein wertvolles Werkzeug für Unternehmen, Investoren und Entscheidungsträger, um sich über den aktuellen Stand des Marktes zu informieren und zukünftige Trends und Entwicklungen vorherzusagen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ICU Medical, Inc. (Nasdaq: ICUI) gab heute bekannt, dass das Management am 44. J.P. Morgan Healthcare Conference in San Francisco vom 12. bis 15. Januar 2026 teilnehmen wird. Die Präsentation ist für den 14. Januar um 13:30 Uhr MEZ (19:30 Uhr PST) geplant, und das Unternehmen wird auch Einzelgespräche führen. Die Präsentation wird live per Stream übertragen und auf der Website (www.icumed.com) für die Wiedergabe verfügbar sein. ICU Medical ist ein weltweit führendes Unternehmen im Bereich Infusionssystemen und kritischer Versorgung.

Would you like me to:

• Adjust the tone of the German translation?
• Create a different version of the summary or translation?